Results from the analysis suggest that denosumab is potentially effective treatment for patients with GCTB of the spine including the sacrum. The adverse event profile was consistent with the full study population.Level of Evidence: 2.
Jianfeng Sun, Masoud Rahmati, Wenqing Xie, Guang Yang, Bingzhou Ji, Dong Keon Yon, Seung Won Lee, Razak M. Gyasi, Guillermo F. López Sánchez, Pınar Soysal, Ai Koyanagi, Lee Smith, Jae Il Shin, Yusheng Li
Robin L. Jones, Jean Yves Blay, Suzanne George, Hans Gelderblom, Patrick Schöffski, Margaret von Mehren, John Zalcberg, Yoon‐Koo Kang, Albiruni Ryan Abdul Razak, Jonathan C. Trent, Steven Attia, Axel Le Cesne, William M. Reichmann, Haroun Achour, Matthew L. Sherman, Rodrigo Ruiz‐Soto, Sebastian Bauer, Michael C. Heinrich
Discussion(0)
No comments yet. Be the first to comment.